These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25185930)

  • 21. Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries.
    Hoey LL; Tschida SJ; Rotschafer JC; Guay DR; Vance-Bryan K
    J Burn Care Rehabil; 1997; 18(2):116-24. PubMed ID: 9095420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
    Mahmoudi L; Mohammadpour AH; Ahmadi A; Niknam R; Mojtahedzadeh M
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):285-91. PubMed ID: 23426530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis.
    Caceres Guido P; Perez M; Halac A; Ferrari M; Ibarra M; Licciardone N; Castaños C; Gravina LP; Jimenez C; Garcia Bournissen F; Schaiquevich P
    Pediatr Pulmonol; 2019 Nov; 54(11):1801-1810. PubMed ID: 31402602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis.
    Roger C; Nucci B; Louart B; Friggeri A; Knani H; Evrard A; Lavigne JP; Allaouchiche B; Lefrant JY; Roberts JA; Muller L
    J Antimicrob Chemother; 2016 Jan; 71(1):208-12. PubMed ID: 26429564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective study.
    Corcione S; De Nicolò A; Lupia T; Segala FV; Pensa A; Corgiat Loia R; Romeo MR; Di Perri G; Stella M; D'Avolio A; De Rosa FG
    Therapie; 2021; 76(5):409-414. PubMed ID: 33257012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimation of once-daily amikacin dose in critically ill adults.
    Šíma M; Hartinger J; Cikánková T; Slanař O
    J Chemother; 2018 Feb; 30(1):37-43. PubMed ID: 28950787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
    Burdet C; Pajot O; Couffignal C; Armand-Lefèvre L; Foucrier A; Laouénan C; Wolff M; Massias L; Mentré F
    Eur J Clin Pharmacol; 2015 Jan; 71(1):75-83. PubMed ID: 25327505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice.
    Smits A; De Cock RF; Allegaert K; Vanhaesebrouck S; Danhof M; Knibbe CA
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6344-51. PubMed ID: 26248375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen.
    de Montmollin E; Bouadma L; Gault N; Mourvillier B; Mariotte E; Chemam S; Massias L; Papy E; Tubach F; Wolff M; Sonneville R
    Intensive Care Med; 2014 Jul; 40(7):998-1005. PubMed ID: 24687298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock.
    Taccone FS; Laterre PF; Spapen H; Dugernier T; Delattre I; Layeux B; De Backer D; Wittebole X; Wallemacq P; Vincent JL; Jacobs F
    Crit Care; 2010; 14(2):R53. PubMed ID: 20370907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the Effects of a High Amikacin Dose on Plasma Peak Concentration in Critically Ill Children.
    Medjebeur Hanna R; Levy M; Bille E; Hennequin C; Lesage F; Naudin J; Moulin F; Blanquer M; Béranger A; Renolleau S; Oualha M; Genuini M
    Paediatr Drugs; 2021 Jul; 23(4):395-401. PubMed ID: 34142330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.
    Pajot O; Burdet C; Couffignal C; Massias L; Armand-Lefevre L; Foucrier A; Da Silva D; Lasocki S; Laouénan C; Mentec H; Mentré F; Wolff M
    J Antimicrob Chemother; 2015 May; 70(5):1487-94. PubMed ID: 25630642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetic/pharmacodynamic evaluations of amikacin dosing in critically ill patients undergoing continuous venovenous hemodiafiltration.
    Li S; Zhu S; Xie F
    J Pharm Pharmacol; 2023 Apr; 75(4):515-522. PubMed ID: 36847263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.
    Tod M; Lortholary O; Seytre D; Semaoun R; Uzzan B; Guillevin L; Casassus P; Petitjean O
    Antimicrob Agents Chemother; 1998 Apr; 42(4):849-56. PubMed ID: 9559795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Lefrant JY; Roberts JA
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4901-9. PubMed ID: 27270279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of amikacin pharmacokinetic/pharmacodynamic index on treatment response in critically ill patients.
    Ruiz J; Ramirez P; Company MJ; Gordon M; Villarreal E; Concha P; Aroca M; Frasquet J; Remedios-Marqués M; Castellanos-Ortega Á
    J Glob Antimicrob Resist; 2018 Mar; 12():90-95. PubMed ID: 29017888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.